PARP1 and ovarian cancer: In platinum-resistant ovarian cancer the niraparib pembrolizumab combination demonstrated an ORR of 25% [78]; this response rate is similar to that of the PARP inhibitor monotherapy in BRCA1/2-mutant patients in this setting [80].